Hikal HIKAL
CDMO and API maker serving pharma and crop-protection innovators
Mapped in 1 theme: Pharmaceuticals.
Where Hikal sits in the supply chain
Hikal appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › CDMO & contract research
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,785 | 1,860 | 1,713 |
| Net profit | 70 | 91 | −49 |
Latest-year revenue ₹1,713 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Long relationships with global innovators in both pharma and agrochemicals
Risks
- FY26 net loss on crop-protection weakness and pharma CDMO delays
- Low returns on capital
Common questions
What does Hikal do?
CDMO and API maker serving pharma and crop-protection innovators.
Where does Hikal sit in the supply chain?
Hikal (NSE: HIKAL) is mapped in 1 supply-chain layer: CDMO & contract research (Pharmaceuticals).
Who are Hikal's peers?
In the CDMO & contract research layer of Pharmaceuticals: Divi's Laboratories, Syngene International, Sai Life Sciences, Anthem Biosciences, Cohance Lifesciences, Piramal Pharma and 4 more.
What is Hikal's market cap and valuation?
As of 30 Oct 2026: market cap ₹2,604 Cr, P/E 61.4x, ROCE 3.5%, ROE 2.2%, dividend yield 0.28%.